CTAP Announcement?, page-16

Perhaps the science is promising.

But....

more data required?

No evidence to suggest that BIT225 has the same 'effectiveness' against Omicron as it has against Delta (as far as investors are aware)

we have no deal

we have no buffer capital to prevent shareholder pain and heartache

we have limited cash to progress further Covid-19 trials, apparently current funds are there to progress only HIV-1 trials to strengthen data results and its commercial attractiveness

What is the 'efficacy' of BIT225 against Delta, Omicron, and all other dominate strains of Sars2?

Are there any strains which BIT225 has limited effectiveness on and would BIT225 be effective against mutated E protein strains

What were the newly synthesized Sars2 compounds that BIT were working and had good data on before BIT225 supposedly popped out of no where when the sp was at all time lows (transparency?)